Higher-risk APS: do we dare to DOAC? Journal Articles

abstract

• In this issue of Blood, Pengo et al present a randomized control trial comparing the use of rivaroxaban and warfarin in high-risk patients with antiphospholipid antibody syndrome (APS). The trial was stopped early because of an increased number of events in the rivaroxaban arm.1

authors

• Laureano, Marissa
• Crowther, Mark

status

• published 

publication date

• September 27, 2018

has subject area

• 1102 Cardiorespiratory Medicine and Haematology (FoR)
• 1103 Clinical Sciences (FoR)
• 1114 Paediatrics and Reproductive Medicine (FoR)
• Anticoagulants (MeSH)
• Antiphospholipid Syndrome (MeSH)
• Humans (MeSH)
• Immunology (Science Metrix)
• Rivaroxaban (MeSH)
• Stroke (MeSH)
• Warfarin (MeSH)

published in

• Blood  Journal

keywords

• Anticoagulants
• Antiphospholipid Syndrome
• Humans
• Rivaroxaban
• Stroke
• Warfarin

Digital Object Identifier (DOI)

• 10.1182/blood-2018-08-867036

PubMed ID

• 30262580

start page

• 1357

end page

• 1358

volume

• 132

issue

• 13